Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 9/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.47 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.47 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1844883 | 1.00 | GRIK1 (0.50) | GRIK1GRIA4GRIK3GRIK5SLC1A1 | |
| SCHEMBL10513370 | 1.00 | GRIK1 (0.50) | GRIK1GRIA4GRIK3GRIK5SLC1A1 | |
| Hydrochloric Acid SCHEMBL21246725 | 0.98 | GRIK1 (0.48) | GRIK1GRIA4GRIK3GRIK5SLC1A1 | |
| SCHEMBL1172846 | 0.84 | MGAM (0.48) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL30722280 | 0.84 | MGAM (0.48) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL1172849 | 0.84 | MGAM (0.48) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL2617390 | 0.84 | MGAM (0.48) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL14456726 | 0.84 | MGAM (0.50) | GRIK1GRIA4GRIK3GRIK5SLC1A1 | |
| SCHEMBL25491149 | 0.84 | GRIK1 (0.48) | GRIK1GRIA4GRIK3GRIK5SLC1A1 | |
| Cyclohexylamine SCHEMBL5689389 | 0.83 | GRIK1 (0.43) | GRIK1GRIA4GRIK3GRIK5SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905527-B2 | Gel composition for culturing cells, production method thereof, method for culturing cells, and substrate for culturing cells | SHIMADZU CORPORATION (JP) | 2024-02-20 | — | — | US | claimed |
| CN-115304516-A | Compounds with unconventional chromophores, their preparation and use | 四川大学 | 2022-11-08 | — | — | CN | claimed |
| CN-104937041-B | Method for preparing self-dispersing pigment | 纳幕尔杜邦公司 | 2017-10-27 | — | — | CN | claimed |
| CN-104919008-B | Method for preparing the silica containing self-dispersing pigment of bag | 纳幕尔杜邦公司 | 2017-07-18 | — | — | CN | claimed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | claimed |
| US-20250177383-A1 | DI-CYCLOPROPYL BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-120040435-A | Mangiferin and derivatives thereof, preparation method and medical application thereof | 安徽中医药大学 | 2025-05-27 | — | — | CN | disclosed |
| US-20250035616-A1 | Organoid Compositions | SHIMADZU CORPORATION (JP) | 2025-01-30 | — | — | US | disclosed |
| EP-4482823-A1 | DI-CYCLOPROPYL BASED IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240399776-A1 | COLOR DEVELOPER, THERMAL RECORDING MATERIAL, AND THERMAL RECORDING LAYER COATING MATERIAL | SANKO CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-115304516-B | Compounds with unconventional chromophores, their preparation and use | 四川大学 | 2024-04-30 | — | — | CN | disclosed |
| US-11905527-B2 | Gel composition for culturing cells, production method thereof, method for culturing cells, and substrate for culturing cells | SHIMADZU CORPORATION (JP) | 2024-02-20 | — | — | US | disclosed |
| WO-1998029419-A1 | CYANOPHOSPHORUS COMPOUNDS AND THEIR PREPARATION | MONSANTO COMPANY (US) | 1998-07-09 | — | — | WO | disclosed |
| WO-1998029422-A1 | CYANOPHOSPHONATE DERIVATIVES | MONSANTO COMPANY (US) | 1998-07-09 | — | — | WO | disclosed |
| EP-0770057-A1 | METHOD FOR PRODUCING CALCIUM SALTS OF [S,S]-ETHYLENEDIAMINE-N,N'-DISUCCINIC ACID | ALBEMARLE CORPORATION (US) | 1997-05-02 | — | — | EP | disclosed |
| US-5550285-A | Method for producing calcium salts of [S,S]-ethylenediamine-N,N'-disuccinic acid | ALBEMARLE CORPORATION | 1996-08-27 | — | — | US | disclosed |
| WO-1996001804-A1 | METHOD FOR PRODUCING CALCIUM SALTS OF [S,S]-ETHYLENEDIAMINE-N,N'-DISUCCINIC ACID | ALBEMARLE CORPORATION (US) | 1996-01-25 | — | — | WO | disclosed |
| US-5278148-A | Hypotensive agents | HOFFMANN-LA ROCHE INC. (US) | 1994-01-11 | — | — | US | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-5140011-A | Hypotensive agents | HOFFMANN-LA ROCHE, INC. (US) | 1992-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177383-A1 | DI-CYCLOPROPYL BASED IL-17A MODULATORS AND USES THEREOF | IL17A, IL23R, IL2 | GRIK1 4116/4885GRIA4 3867/4885GRIK3 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.